Intro about the company
Novartis is reimagining medicine to improve and extend people’s lives. While finding innovative ways to expand access to treatments and improve access to healthcare, Novartis products reach nearly 800 million people worldwide. More than 100,000 people of more than 140 nationalities work at Novartis around the world.
Novartis’ strives to provide patients, healthcare professionals and caregivers with safe, effective and efficient care. By following its clear ambition – to be a leading medicines company powered by data and digital – Novartis is open to combine the power of external innovation with industry expertise: to drive medical research and development through the potential of data science, digital technologies and artificial intelligence.
Read more about Novartis (https://www.novartis.com/) and its efforts together with Sandoz Germany in supporting creative minds with the Digital Health Award (Digitaler Gesundheitspreis, submission deadline Nov 30th) (http://www.novartis.de/dgp)
The call of applications
In order to further advance the development of innovative solutions, Novartis is hosting an innovation challenge at Frontiers Health 2020. Startups and innovation-driven companies working on the following topics are invited to participate. As the pitch event will be held fully virtual, we are happy to receive suggestions from all over the world:
1. How can real world data be accessed and used for advanced research and personalized therapy in cancer?
Real world health data holds great potential for research and personalized medicine. However, gathering, accessing, analyzing and using this data is still a big challenge. Solutions could for example focus on facilitating and enhancing data donations from patients via electronic patient records, health apps and wearables. Another possibility would be to focus on enabling the use of public available health data such as data from health registries. If your solution helps generating, accessing, cleaning, linking or analyzing data, your application is welcome!
2. How can nAMD patients, who receive anti-VEGF drugs, be monitored for ocular inflammation outside of the physician’s office?
Anti-VEGF (vascular endothelial growth factor) drugs are used for the treatment of nAMD (neovascular age-related macular degeneration). Possible side effects are ocular inflammations, which can have severe and irreversible consequences, eventually resulting in blindness. We are looking for solutions that help to (self-)test, self-manage or monitor patients who receive anti-VEGF drugs to detect ocular inflammations at an early stage.
Novartis encourages startups and tech companies to share and discuss their innovation with them. If you have already passed the ideation phase and are working on a first prototype or more mature solution, Novartis is looking forward to your application.
What’s in there for startups
A selection of the best fitting startups will have the chance to pitch their solution to a board of Novartis experts and decision makers. For the most promising ideas, Novartis will evaluate the potential of a collaboration.
Call to action
Your solution fits one of these challenges? You want to take your business further and join forces with a global leader in the pharmaceutical industry? Use this opportunity to pitch your idea and join Novartis on the journey to reimagine medicine by going big on data and digital! Apply here no later than October 31st.
Orion returns at Frontiers Health 2022 to unleash the power of digital therapeutics for chronic pain
Connecting patients and clinicians wherever they are. Teladoc Health brings their transformative technology to FH22!
Supporting innovation and expanding global access to care. StartUp Health is back to Frontiers Health!
Transformative places collide as Frontiers Health returns to Milan at a new location, Palazzo del Ghiaccio, for its 2022 Edition
Deploying and scaling validated digital health solutions. Wellthy and Frontiers Health to enhance their partnership at FH22
IF YOU WOULD LIKE TO TAKE PART IN THE EVENT,
OR BE THE FIRST TO FIND OUT ABOUT OUR 2019 EDITION